| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biliary Atresia | 37 | 2024 | 201 | 10.110 |
Why?
|
| Liver Transplantation | 70 | 2023 | 1034 | 6.140 |
Why?
|
| Hypertension, Portal | 18 | 2024 | 80 | 4.460 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 23 | 2014 | 28 | 4.410 |
Why?
|
| Cholestasis, Intrahepatic | 20 | 2023 | 67 | 4.340 |
Why?
|
| Symporters | 23 | 2014 | 66 | 4.270 |
Why?
|
| Portoenterostomy, Hepatic | 13 | 2024 | 55 | 3.480 |
Why?
|
| Cholestasis | 22 | 2024 | 161 | 3.430 |
Why?
|
| Bilirubin | 16 | 2023 | 129 | 3.100 |
Why?
|
| Bile Acids and Salts | 34 | 2023 | 237 | 2.850 |
Why?
|
| Ileum | 21 | 2021 | 134 | 2.670 |
Why?
|
| Esophageal and Gastric Varices | 8 | 2024 | 64 | 2.470 |
Why?
|
| Liver Diseases | 15 | 2023 | 384 | 2.340 |
Why?
|
| Liver | 41 | 2023 | 1858 | 2.250 |
Why?
|
| Alagille Syndrome | 7 | 2022 | 47 | 1.810 |
Why?
|
| Carrier Proteins | 23 | 2005 | 1024 | 1.690 |
Why?
|
| Liver Failure, Acute | 11 | 2018 | 88 | 1.680 |
Why?
|
| Infant | 77 | 2024 | 12355 | 1.670 |
Why?
|
| Adenosine Triphosphatases | 11 | 2021 | 210 | 1.650 |
Why?
|
| ATP-Binding Cassette Transporters | 16 | 2021 | 191 | 1.640 |
Why?
|
| Liver Failure | 9 | 2012 | 93 | 1.630 |
Why?
|
| Neonatal Screening | 6 | 2021 | 187 | 1.520 |
Why?
|
| Child | 111 | 2024 | 24170 | 1.500 |
Why?
|
| Gastrointestinal Hemorrhage | 7 | 2024 | 224 | 1.360 |
Why?
|
| Immunosuppressive Agents | 19 | 2020 | 646 | 1.330 |
Why?
|
| Gastroenterology | 5 | 2024 | 190 | 1.320 |
Why?
|
| Humans | 210 | 2024 | 122971 | 1.300 |
Why?
|
| Liver Cirrhosis | 10 | 2023 | 830 | 1.280 |
Why?
|
| Cholangitis | 4 | 2023 | 35 | 1.270 |
Why?
|
| Hepatolenticular Degeneration | 5 | 2016 | 36 | 1.200 |
Why?
|
| Hepatitis, Autoimmune | 8 | 2012 | 47 | 1.190 |
Why?
|
| Graft Rejection | 17 | 2020 | 584 | 1.180 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 5 | 2014 | 9 | 1.120 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 13 | 2016 | 392 | 1.120 |
Why?
|
| Enterocytes | 3 | 2021 | 70 | 1.110 |
Why?
|
| Infant, Newborn | 43 | 2024 | 8120 | 1.040 |
Why?
|
| Varicose Veins | 2 | 2022 | 28 | 1.020 |
Why?
|
| Portal Vein | 5 | 2015 | 92 | 1.010 |
Why?
|
| Child, Preschool | 60 | 2021 | 13858 | 1.000 |
Why?
|
| Proto-Oncogene Proteins c-fos | 4 | 2013 | 64 | 0.960 |
Why?
|
| Pruritus | 7 | 2022 | 41 | 0.950 |
Why?
|
| Avitaminosis | 3 | 2015 | 4 | 0.940 |
Why?
|
| Patient Compliance | 9 | 2017 | 465 | 0.930 |
Why?
|
| Pediatrics | 12 | 2024 | 1142 | 0.930 |
Why?
|
| Treatment Outcome | 44 | 2024 | 12083 | 0.920 |
Why?
|
| Male | 113 | 2024 | 59957 | 0.910 |
Why?
|
| Cholagogues and Choleretics | 6 | 2016 | 25 | 0.900 |
Why?
|
| Infant Formula | 1 | 2024 | 98 | 0.890 |
Why?
|
| Ursodeoxycholic Acid | 7 | 2016 | 37 | 0.890 |
Why?
|
| ELAV Proteins | 2 | 2014 | 13 | 0.860 |
Why?
|
| Cholangitis, Sclerosing | 5 | 2012 | 54 | 0.850 |
Why?
|
| Female | 102 | 2024 | 65361 | 0.850 |
Why?
|
| End Stage Liver Disease | 3 | 2018 | 178 | 0.830 |
Why?
|
| RNA Stability | 2 | 2014 | 85 | 0.820 |
Why?
|
| Hepatorenal Syndrome | 1 | 2022 | 27 | 0.820 |
Why?
|
| Bile Ducts | 6 | 2016 | 64 | 0.790 |
Why?
|
| Adolescent | 59 | 2023 | 19043 | 0.780 |
Why?
|
| Fellowships and Scholarships | 2 | 2024 | 270 | 0.780 |
Why?
|
| Hydroxysteroid Dehydrogenases | 8 | 2002 | 19 | 0.780 |
Why?
|
| Milk, Human | 1 | 2024 | 295 | 0.770 |
Why?
|
| Hemochromatosis | 5 | 2004 | 33 | 0.760 |
Why?
|
| Membrane Glycoproteins | 10 | 2006 | 415 | 0.750 |
Why?
|
| Biliary Tract Diseases | 5 | 2006 | 35 | 0.730 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2021 | 39 | 0.730 |
Why?
|
| Protein Kinase C | 3 | 2012 | 151 | 0.720 |
Why?
|
| Intestinal Neoplasms | 1 | 2021 | 40 | 0.720 |
Why?
|
| Hepatopulmonary Syndrome | 3 | 2010 | 8 | 0.710 |
Why?
|
| Gallbladder | 5 | 2017 | 19 | 0.700 |
Why?
|
| Fibroblast Growth Factors | 2 | 2013 | 155 | 0.700 |
Why?
|
| Giant Cells | 4 | 2012 | 35 | 0.680 |
Why?
|
| Mutation | 18 | 2021 | 5794 | 0.670 |
Why?
|
| Caco-2 Cells | 11 | 2013 | 96 | 0.670 |
Why?
|
| Curriculum | 2 | 2024 | 718 | 0.660 |
Why?
|
| DNA-Binding Proteins | 11 | 2008 | 2060 | 0.650 |
Why?
|
| Prognosis | 15 | 2023 | 4503 | 0.640 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2019 | 106 | 0.640 |
Why?
|
| Rats | 25 | 2014 | 3665 | 0.610 |
Why?
|
| Prospective Studies | 20 | 2024 | 6020 | 0.600 |
Why?
|
| Consensus | 2 | 2019 | 606 | 0.580 |
Why?
|
| Medication Adherence | 6 | 2023 | 385 | 0.580 |
Why?
|
| Early Diagnosis | 1 | 2018 | 181 | 0.570 |
Why?
|
| Alanine Transaminase | 7 | 2020 | 155 | 0.570 |
Why?
|
| Cytokines | 2 | 2023 | 1287 | 0.570 |
Why?
|
| Transcription Factors | 11 | 2008 | 2589 | 0.560 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 121 | 0.550 |
Why?
|
| Telemedicine | 1 | 2022 | 421 | 0.540 |
Why?
|
| 3' Untranslated Regions | 2 | 2014 | 166 | 0.540 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 164 | 0.530 |
Why?
|
| Tissue and Organ Procurement | 5 | 2018 | 218 | 0.530 |
Why?
|
| Hepatocytes | 4 | 2016 | 257 | 0.530 |
Why?
|
| Retrospective Studies | 27 | 2023 | 15934 | 0.530 |
Why?
|
| Phenylacetates | 1 | 2016 | 23 | 0.530 |
Why?
|
| Vitamin K | 2 | 2014 | 35 | 0.520 |
Why?
|
| Vitamin E | 2 | 2014 | 64 | 0.520 |
Why?
|
| Bile | 6 | 2020 | 47 | 0.520 |
Why?
|
| Disease Progression | 8 | 2017 | 2029 | 0.510 |
Why?
|
| Telecommunications | 1 | 2015 | 19 | 0.510 |
Why?
|
| Promoter Regions, Genetic | 13 | 2012 | 1354 | 0.510 |
Why?
|
| Tristetraprolin | 2 | 2014 | 6 | 0.510 |
Why?
|
| Phenylbutyrates | 1 | 2016 | 54 | 0.510 |
Why?
|
| gamma-Glutamyltransferase | 4 | 2015 | 41 | 0.490 |
Why?
|
| Microbiota | 1 | 2020 | 392 | 0.490 |
Why?
|
| Rifampin | 1 | 2016 | 145 | 0.490 |
Why?
|
| Clinical Competence | 2 | 2024 | 977 | 0.490 |
Why?
|
| Ileitis | 2 | 2006 | 10 | 0.480 |
Why?
|
| Antiviral Agents | 4 | 2009 | 736 | 0.480 |
Why?
|
| Biliary Tract Surgical Procedures | 4 | 2017 | 23 | 0.480 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2013 | 243 | 0.470 |
Why?
|
| Gene Expression Regulation | 12 | 2014 | 2541 | 0.450 |
Why?
|
| Diagnosis, Differential | 4 | 2017 | 1881 | 0.450 |
Why?
|
| Patient Selection | 5 | 2017 | 684 | 0.450 |
Why?
|
| Cell Nucleus | 6 | 2013 | 679 | 0.450 |
Why?
|
| Animals | 45 | 2021 | 33923 | 0.450 |
Why?
|
| Dietary Supplements | 3 | 2022 | 462 | 0.440 |
Why?
|
| Immunologic Factors | 2 | 2012 | 179 | 0.440 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2012 | 63 | 0.430 |
Why?
|
| Phospholipase D | 1 | 2012 | 7 | 0.430 |
Why?
|
| Signal Transduction | 5 | 2013 | 4524 | 0.420 |
Why?
|
| Organ Transplantation | 4 | 2017 | 163 | 0.420 |
Why?
|
| RNA, Messenger | 16 | 2014 | 2833 | 0.410 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2012 | 49 | 0.400 |
Why?
|
| Transfection | 7 | 2013 | 1076 | 0.400 |
Why?
|
| Interferon-alpha | 3 | 2005 | 221 | 0.400 |
Why?
|
| Surveys and Questionnaires | 8 | 2023 | 3648 | 0.390 |
Why?
|
| Insurance Coverage | 1 | 2013 | 121 | 0.390 |
Why?
|
| Biomarkers | 6 | 2024 | 2952 | 0.390 |
Why?
|
| United States | 20 | 2023 | 10564 | 0.380 |
Why?
|
| Time Factors | 18 | 2019 | 6216 | 0.380 |
Why?
|
| Intestinal Mucosa | 7 | 2010 | 774 | 0.380 |
Why?
|
| Glycogen Storage Disease Type III | 1 | 2011 | 2 | 0.380 |
Why?
|
| Bile Canaliculi | 2 | 2015 | 5 | 0.380 |
Why?
|
| Propionic Acidemia | 1 | 2011 | 10 | 0.380 |
Why?
|
| Severity of Illness Index | 6 | 2018 | 2846 | 0.380 |
Why?
|
| Hepatitis B, Chronic | 2 | 2005 | 84 | 0.380 |
Why?
|
| Kidney Transplantation | 6 | 2019 | 629 | 0.370 |
Why?
|
| Transplantation | 2 | 2008 | 29 | 0.360 |
Why?
|
| Sarcopenia | 2 | 2023 | 38 | 0.360 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1001 | 0.360 |
Why?
|
| Acidosis | 1 | 2011 | 93 | 0.350 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 2 | 2023 | 40 | 0.350 |
Why?
|
| Argininosuccinate Lyase | 2 | 2021 | 60 | 0.350 |
Why?
|
| Graft Survival | 7 | 2017 | 526 | 0.350 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 5025 | 0.340 |
Why?
|
| Mass Screening | 3 | 2009 | 786 | 0.340 |
Why?
|
| Sensitivity and Specificity | 6 | 2020 | 2025 | 0.340 |
Why?
|
| Lymphoproliferative Disorders | 4 | 2010 | 224 | 0.340 |
Why?
|
| Valproic Acid | 1 | 2010 | 165 | 0.340 |
Why?
|
| Waiting Lists | 5 | 2018 | 224 | 0.340 |
Why?
|
| Taurocholic Acid | 7 | 1998 | 9 | 0.340 |
Why?
|
| Azathioprine | 4 | 2005 | 54 | 0.340 |
Why?
|
| Ascites | 2 | 2022 | 88 | 0.330 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 234 | 0.330 |
Why?
|
| Blotting, Western | 8 | 2013 | 1106 | 0.320 |
Why?
|
| Adult | 31 | 2021 | 28944 | 0.320 |
Why?
|
| Rats, Sprague-Dawley | 12 | 2010 | 1217 | 0.320 |
Why?
|
| Proteins | 1 | 2014 | 1045 | 0.320 |
Why?
|
| Postoperative Complications | 12 | 2015 | 3002 | 0.320 |
Why?
|
| Cholesterol | 7 | 2003 | 522 | 0.320 |
Why?
|
| Growth Disorders | 3 | 2018 | 209 | 0.320 |
Why?
|
| Fatty Liver | 2 | 2009 | 182 | 0.320 |
Why?
|
| Treatment Refusal | 4 | 2007 | 77 | 0.310 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2010 | 285 | 0.310 |
Why?
|
| Biopsy | 8 | 2020 | 1256 | 0.310 |
Why?
|
| Cohort Studies | 12 | 2024 | 4688 | 0.310 |
Why?
|
| Survival Rate | 7 | 2015 | 1999 | 0.310 |
Why?
|
| Tacrolimus | 7 | 2017 | 99 | 0.310 |
Why?
|
| Blotting, Northern | 6 | 2011 | 260 | 0.310 |
Why?
|
| Nutrition Disorders | 2 | 2023 | 32 | 0.310 |
Why?
|
| Predictive Value of Tests | 6 | 2020 | 2104 | 0.300 |
Why?
|
| Hepatitis | 3 | 2007 | 65 | 0.300 |
Why?
|
| Liver Circulation | 1 | 2007 | 24 | 0.300 |
Why?
|
| Transaminases | 2 | 2007 | 33 | 0.300 |
Why?
|
| Transcription Factor AP-1 | 2 | 2013 | 107 | 0.300 |
Why?
|
| Gene Deletion | 2 | 2021 | 799 | 0.290 |
Why?
|
| Premature Birth | 2 | 2022 | 380 | 0.290 |
Why?
|
| Chelating Agents | 1 | 2007 | 43 | 0.280 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2024 | 21 | 0.280 |
Why?
|
| Chenodeoxycholic Acid | 3 | 2004 | 14 | 0.280 |
Why?
|
| Hepatitis C | 4 | 2006 | 368 | 0.280 |
Why?
|
| Copper | 1 | 2007 | 68 | 0.280 |
Why?
|
| Metabolic Diseases | 2 | 2014 | 130 | 0.280 |
Why?
|
| Kidney | 6 | 2008 | 1346 | 0.270 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1682 | 0.270 |
Why?
|
| Liver Function Tests | 5 | 2019 | 103 | 0.270 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 6 | 2003 | 36 | 0.270 |
Why?
|
| Liver Neoplasms | 5 | 2010 | 1389 | 0.270 |
Why?
|
| Resource Allocation | 1 | 2006 | 52 | 0.260 |
Why?
|
| Jaundice | 2 | 2015 | 28 | 0.260 |
Why?
|
| Biological Transport | 8 | 2005 | 347 | 0.250 |
Why?
|
| Longitudinal Studies | 8 | 2021 | 1308 | 0.250 |
Why?
|
| Risk Factors | 15 | 2023 | 9950 | 0.250 |
Why?
|
| Decision Support Techniques | 2 | 2006 | 280 | 0.250 |
Why?
|
| Luciferases | 3 | 2013 | 137 | 0.250 |
Why?
|
| Recurrence | 10 | 2010 | 1419 | 0.250 |
Why?
|
| Hepatitis B | 1 | 2006 | 162 | 0.250 |
Why?
|
| Lamivudine | 1 | 2005 | 25 | 0.240 |
Why?
|
| Feces | 2 | 2008 | 711 | 0.240 |
Why?
|
| Health Care Rationing | 1 | 2005 | 58 | 0.240 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 1086 | 0.240 |
Why?
|
| Awards and Prizes | 1 | 2006 | 63 | 0.240 |
Why?
|
| Up-Regulation | 5 | 2010 | 874 | 0.240 |
Why?
|
| Registries | 3 | 2024 | 1381 | 0.240 |
Why?
|
| Double-Blind Method | 5 | 2018 | 1576 | 0.240 |
Why?
|
| Carnitine | 1 | 2005 | 78 | 0.240 |
Why?
|
| Hepatitis C, Chronic | 2 | 2006 | 319 | 0.240 |
Why?
|
| Cytoplasm | 3 | 2013 | 290 | 0.240 |
Why?
|
| Living Donors | 4 | 2013 | 111 | 0.230 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 3342 | 0.230 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 317 | 0.230 |
Why?
|
| Electrophoretic Mobility Shift Assay | 3 | 2014 | 48 | 0.230 |
Why?
|
| Young Adult | 12 | 2023 | 8830 | 0.230 |
Why?
|
| Molecular Sequence Data | 8 | 2005 | 3888 | 0.230 |
Why?
|
| Internationality | 1 | 2024 | 130 | 0.230 |
Why?
|
| Mice | 13 | 2021 | 17647 | 0.230 |
Why?
|
| Jaundice, Chronic Idiopathic | 1 | 2003 | 1 | 0.220 |
Why?
|
| Metabolism, Inborn Errors | 2 | 2021 | 104 | 0.220 |
Why?
|
| Herpesvirus 4, Human | 3 | 2006 | 663 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 2 | 2020 | 219 | 0.220 |
Why?
|
| Sepsis | 1 | 2008 | 479 | 0.220 |
Why?
|
| Cell Line | 8 | 2008 | 2787 | 0.220 |
Why?
|
| Plasmids | 3 | 2013 | 516 | 0.220 |
Why?
|
| Vitamin A | 2 | 2014 | 61 | 0.220 |
Why?
|
| Ligation | 2 | 2015 | 134 | 0.220 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2022 | 126 | 0.220 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2023 | 55 | 0.220 |
Why?
|
| Urea Cycle Disorders, Inborn | 2 | 2021 | 78 | 0.220 |
Why?
|
| Jaundice, Neonatal | 2 | 2002 | 13 | 0.210 |
Why?
|
| Membrane Proteins | 2 | 2008 | 1529 | 0.210 |
Why?
|
| Cystic Fibrosis | 1 | 2006 | 261 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-jun | 3 | 2013 | 46 | 0.210 |
Why?
|
| Cloning, Molecular | 4 | 2001 | 900 | 0.210 |
Why?
|
| Hyperlipoproteinemia Type V | 1 | 2002 | 1 | 0.210 |
Why?
|
| Age Factors | 6 | 2020 | 2799 | 0.210 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 805 | 0.200 |
Why?
|
| Homeostasis | 4 | 2011 | 682 | 0.200 |
Why?
|
| Peritonitis | 1 | 2022 | 76 | 0.200 |
Why?
|
| Eosinophilia | 1 | 2004 | 102 | 0.200 |
Why?
|
| Ceruloplasmin | 1 | 2002 | 13 | 0.200 |
Why?
|
| Interleukin-12 | 1 | 2023 | 116 | 0.200 |
Why?
|
| Stress Disorders, Post-Traumatic | 5 | 2006 | 621 | 0.200 |
Why?
|
| Cells, Cultured | 4 | 2011 | 3075 | 0.200 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 1301 | 0.200 |
Why?
|
| Canada | 4 | 2018 | 294 | 0.200 |
Why?
|
| Vitamin D | 2 | 2014 | 159 | 0.200 |
Why?
|
| Intestines | 3 | 2011 | 580 | 0.200 |
Why?
|
| Quality of Life | 6 | 2023 | 1921 | 0.200 |
Why?
|
| Base Sequence | 7 | 2004 | 3118 | 0.190 |
Why?
|
| Citrullinemia | 1 | 2001 | 15 | 0.190 |
Why?
|
| Genes, MDR | 1 | 2001 | 6 | 0.190 |
Why?
|
| Reference Values | 2 | 2020 | 699 | 0.190 |
Why?
|
| Endoscopy | 2 | 2015 | 283 | 0.190 |
Why?
|
| Hep G2 Cells | 2 | 2012 | 92 | 0.190 |
Why?
|
| Consensus Development Conferences as Topic | 3 | 2012 | 39 | 0.190 |
Why?
|
| Intestinal Absorption | 2 | 2001 | 191 | 0.190 |
Why?
|
| Research | 2 | 2005 | 261 | 0.190 |
Why?
|
| Diethylhexyl Phthalate | 2 | 1991 | 5 | 0.180 |
Why?
|
| Hepatitis A | 1 | 2000 | 32 | 0.180 |
Why?
|
| Cholecystitis | 1 | 2000 | 20 | 0.180 |
Why?
|
| Failure to Thrive | 2 | 2018 | 91 | 0.180 |
Why?
|
| Transcription, Genetic | 4 | 2001 | 1703 | 0.180 |
Why?
|
| Monocytes | 1 | 2023 | 348 | 0.180 |
Why?
|
| alpha 1-Antitrypsin | 2 | 2023 | 97 | 0.180 |
Why?
|
| Diabetes, Gestational | 1 | 2022 | 107 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 1006 | 0.170 |
Why?
|
| Liver Glycogen | 1 | 2020 | 25 | 0.170 |
Why?
|
| Bile Ducts, Intrahepatic | 6 | 2021 | 99 | 0.170 |
Why?
|
| Dendritic Cells | 1 | 2023 | 405 | 0.170 |
Why?
|
| Portasystemic Shunt, Surgical | 2 | 2012 | 8 | 0.170 |
Why?
|
| Immunity, Innate | 1 | 2023 | 374 | 0.170 |
Why?
|
| Abdominal Pain | 1 | 2022 | 308 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 250 | 0.170 |
Why?
|
| Minocycline | 1 | 2000 | 36 | 0.170 |
Why?
|
| Longevity | 1 | 2021 | 120 | 0.170 |
Why?
|
| Gene Expression | 4 | 2006 | 1592 | 0.170 |
Why?
|
| Tissue Donors | 4 | 2011 | 497 | 0.170 |
Why?
|
| Vitamins | 2 | 2022 | 106 | 0.160 |
Why?
|
| Drug Approval | 1 | 1999 | 39 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 510 | 0.160 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2019 | 77 | 0.160 |
Why?
|
| Ultrasonography | 4 | 2021 | 946 | 0.160 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 2824 | 0.160 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 866 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 320 | 0.160 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 1991 | 627 | 0.160 |
Why?
|
| Cricetinae | 3 | 2012 | 411 | 0.160 |
Why?
|
| Allylamine | 1 | 1998 | 8 | 0.160 |
Why?
|
| Common Bile Duct | 1 | 1998 | 16 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2019 | 98 | 0.160 |
Why?
|
| Congresses as Topic | 3 | 2015 | 164 | 0.160 |
Why?
|
| In Vitro Techniques | 3 | 2011 | 969 | 0.160 |
Why?
|
| Aging | 2 | 1996 | 1175 | 0.160 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 582 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 187 | 0.150 |
Why?
|
| Inflammation | 3 | 2023 | 1401 | 0.150 |
Why?
|
| Risk Assessment | 6 | 2021 | 3319 | 0.150 |
Why?
|
| Complement Factor H | 2 | 2008 | 18 | 0.150 |
Why?
|
| Membrane Transport Proteins | 3 | 2005 | 176 | 0.150 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 866 | 0.150 |
Why?
|
| North America | 2 | 2012 | 235 | 0.150 |
Why?
|
| Binding Sites | 3 | 2014 | 1294 | 0.150 |
Why?
|
| Prenatal Diagnosis | 2 | 2019 | 581 | 0.140 |
Why?
|
| Terminology as Topic | 1 | 2019 | 226 | 0.140 |
Why?
|
| Hemolytic-Uremic Syndrome | 2 | 2008 | 36 | 0.140 |
Why?
|
| Enterohepatic Circulation | 1 | 2017 | 10 | 0.140 |
Why?
|
| Survival Analysis | 4 | 2021 | 1473 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 118 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 6 | 2010 | 1598 | 0.140 |
Why?
|
| Genotype | 5 | 2010 | 2536 | 0.140 |
Why?
|
| Adaptation, Physiological | 1 | 1998 | 265 | 0.140 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 446 | 0.140 |
Why?
|
| Affect | 1 | 2018 | 154 | 0.140 |
Why?
|
| Puerto Rico | 1 | 2016 | 41 | 0.140 |
Why?
|
| Chronic Disease | 4 | 2020 | 1170 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2021 | 3084 | 0.140 |
Why?
|
| Mutation, Missense | 1 | 2001 | 846 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 664 | 0.140 |
Why?
|
| Bone Density | 1 | 2018 | 309 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 84 | 0.130 |
Why?
|
| Animals, Newborn | 2 | 1997 | 1007 | 0.130 |
Why?
|
| Self-Management | 1 | 2017 | 96 | 0.130 |
Why?
|
| Sodium | 5 | 2001 | 290 | 0.130 |
Why?
|
| Rabbits | 7 | 2005 | 717 | 0.130 |
Why?
|
| Hypoalbuminemia | 1 | 2015 | 18 | 0.130 |
Why?
|
| Prednisolone | 2 | 2014 | 73 | 0.130 |
Why?
|
| Prevalence | 4 | 2022 | 2390 | 0.130 |
Why?
|
| Referral and Consultation | 2 | 2018 | 528 | 0.130 |
Why?
|
| Sclerotherapy | 1 | 2015 | 40 | 0.130 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2015 | 67 | 0.130 |
Why?
|
| Microvilli | 3 | 2002 | 73 | 0.130 |
Why?
|
| Hyperbilirubinemia | 2 | 2015 | 43 | 0.130 |
Why?
|
| Choledochostomy | 1 | 2015 | 5 | 0.120 |
Why?
|
| Drug Therapy, Combination | 3 | 2006 | 1151 | 0.120 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2014 | 8 | 0.120 |
Why?
|
| Postoperative Care | 2 | 2018 | 292 | 0.120 |
Why?
|
| Pancreas | 1 | 1996 | 214 | 0.120 |
Why?
|
| Transplantation Conditioning | 1 | 2016 | 323 | 0.120 |
Why?
|
| Pandemics | 1 | 2022 | 1104 | 0.120 |
Why?
|
| Sleep | 1 | 2018 | 346 | 0.120 |
Why?
|
| Cytomegalovirus | 3 | 2020 | 269 | 0.120 |
Why?
|
| Qualitative Research | 1 | 2018 | 519 | 0.120 |
Why?
|
| Pancreatitis | 1 | 1996 | 130 | 0.120 |
Why?
|
| Interleukin-1 | 2 | 2006 | 141 | 0.120 |
Why?
|
| Down-Regulation | 4 | 2005 | 702 | 0.120 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 923 | 0.120 |
Why?
|
| Placebos | 1 | 2014 | 239 | 0.120 |
Why?
|
| Disease Management | 1 | 2018 | 514 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2015 | 163 | 0.120 |
Why?
|
| Abnormalities, Multiple | 2 | 2013 | 973 | 0.110 |
Why?
|
| Health Status | 2 | 2014 | 373 | 0.110 |
Why?
|
| Butadienes | 1 | 2013 | 19 | 0.110 |
Why?
|
| Methylprednisolone | 1 | 2014 | 90 | 0.110 |
Why?
|
| Rituximab | 2 | 2012 | 158 | 0.110 |
Why?
|
| Biliary Tract | 3 | 2005 | 19 | 0.110 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2004 | 74 | 0.110 |
Why?
|
| Fetus | 1 | 1997 | 579 | 0.110 |
Why?
|
| Point Mutation | 3 | 2006 | 347 | 0.110 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2004 | 318 | 0.110 |
Why?
|
| Oxidoreductases | 1 | 1994 | 92 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2008 | 961 | 0.110 |
Why?
|
| Cell Membrane | 3 | 2013 | 460 | 0.110 |
Why?
|
| Flavonoids | 1 | 2013 | 78 | 0.110 |
Why?
|
| Postoperative Period | 4 | 2008 | 330 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1936 | 0.110 |
Why?
|
| Nitriles | 1 | 2013 | 145 | 0.110 |
Why?
|
| Developmental Disabilities | 1 | 2018 | 695 | 0.110 |
Why?
|
| Prothrombin Time | 1 | 2012 | 36 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 1247 | 0.100 |
Why?
|
| Parents | 4 | 2017 | 1017 | 0.100 |
Why?
|
| Cricetulus | 1 | 2012 | 101 | 0.100 |
Why?
|
| Virilism | 1 | 1992 | 14 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 207 | 0.100 |
Why?
|
| CHO Cells | 1 | 2012 | 159 | 0.100 |
Why?
|
| Retinol-Binding Proteins | 1 | 2012 | 22 | 0.100 |
Why?
|
| Aspartate Aminotransferases | 1 | 2012 | 76 | 0.100 |
Why?
|
| Transplant Recipients | 1 | 2014 | 210 | 0.100 |
Why?
|
| Amino Acid Sequence | 4 | 2005 | 2702 | 0.100 |
Why?
|
| Splenomegaly | 1 | 2012 | 34 | 0.100 |
Why?
|
| alpha-Tocopherol | 1 | 2012 | 37 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2015 | 1164 | 0.100 |
Why?
|
| Platelet Count | 1 | 2012 | 133 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 1412 | 0.100 |
Why?
|
| Lennox Gastaut Syndrome | 1 | 2012 | 7 | 0.100 |
Why?
|
| Logistic Models | 2 | 2015 | 1788 | 0.100 |
Why?
|
| Acetylcysteine | 1 | 2013 | 74 | 0.100 |
Why?
|
| Serum Albumin | 1 | 2012 | 110 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 1689 | 0.100 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1992 | 44 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 2 | 2009 | 337 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2012 | 249 | 0.100 |
Why?
|
| Social Class | 1 | 2013 | 181 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2012 | 238 | 0.100 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2002 | 287 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 816 | 0.100 |
Why?
|
| Maple Syrup Urine Disease | 1 | 2011 | 15 | 0.100 |
Why?
|
| Methylmalonyl-CoA Decarboxylase | 1 | 2011 | 1 | 0.100 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2011 | 51 | 0.100 |
Why?
|
| Pennsylvania | 4 | 2018 | 49 | 0.100 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 217 | 0.090 |
Why?
|
| Cholesterol, Dietary | 2 | 2001 | 46 | 0.090 |
Why?
|
| Models, Genetic | 2 | 2005 | 748 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 1992 | 151 | 0.090 |
Why?
|
| Steroid Hydroxylases | 4 | 2003 | 20 | 0.090 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2010 | 7 | 0.090 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 230 | 0.090 |
Why?
|
| Mesenteric Veins | 1 | 2010 | 15 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 570 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2005 | 658 | 0.090 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 2 | 2007 | 28 | 0.090 |
Why?
|
| Spasms, Infantile | 1 | 2012 | 169 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 564 | 0.090 |
Why?
|
| Cholangiography | 3 | 2008 | 15 | 0.090 |
Why?
|
| Leukocytes | 1 | 2011 | 207 | 0.090 |
Why?
|
| Brazil | 1 | 2010 | 122 | 0.090 |
Why?
|
| Fatal Outcome | 2 | 2001 | 359 | 0.090 |
Why?
|
| Risk | 2 | 2018 | 747 | 0.080 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2010 | 112 | 0.080 |
Why?
|
| Protein Binding | 2 | 2005 | 1738 | 0.080 |
Why?
|
| Middle Aged | 7 | 2021 | 25885 | 0.080 |
Why?
|
| Phthalic Acids | 1 | 1989 | 7 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2010 | 139 | 0.080 |
Why?
|
| Child Development | 2 | 2018 | 250 | 0.080 |
Why?
|
| Case-Control Studies | 4 | 2005 | 3257 | 0.080 |
Why?
|
| Ganciclovir | 1 | 2009 | 105 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 3 | 1998 | 108 | 0.080 |
Why?
|
| Haplorhini | 1 | 2008 | 127 | 0.080 |
Why?
|
| Mice, Knockout | 4 | 2006 | 3782 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2001 | 3524 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2023 | 677 | 0.080 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 3 | 2003 | 12 | 0.080 |
Why?
|
| Personality Inventory | 2 | 2006 | 166 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2008 | 4392 | 0.080 |
Why?
|
| Viral Load | 2 | 2001 | 384 | 0.080 |
Why?
|
| Psychology, Child | 2 | 2005 | 45 | 0.080 |
Why?
|
| Pedigree | 3 | 2008 | 1580 | 0.080 |
Why?
|
| Color | 1 | 2008 | 30 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 2396 | 0.080 |
Why?
|
| RNA Interference | 1 | 2010 | 497 | 0.080 |
Why?
|
| Syndrome | 2 | 2002 | 1123 | 0.070 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 3 | 2002 | 27 | 0.070 |
Why?
|
| Phlebography | 1 | 2007 | 51 | 0.070 |
Why?
|
| Anticonvulsants | 1 | 2010 | 372 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2004 | 1007 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2010 | 351 | 0.070 |
Why?
|
| Trientine | 1 | 2007 | 1 | 0.070 |
Why?
|
| Macrophages | 1 | 2011 | 613 | 0.070 |
Why?
|
| Molecular Weight | 3 | 1997 | 393 | 0.070 |
Why?
|
| Human Growth Hormone | 1 | 2007 | 74 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 392 | 0.070 |
Why?
|
| Turner Syndrome | 1 | 2007 | 47 | 0.070 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 213 | 0.070 |
Why?
|
| Species Specificity | 2 | 2005 | 552 | 0.070 |
Why?
|
| Ethics, Medical | 1 | 2010 | 395 | 0.070 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 303 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2007 | 169 | 0.070 |
Why?
|
| Phenotype | 6 | 2023 | 4222 | 0.070 |
Why?
|
| Pemphigoid, Bullous | 1 | 2006 | 5 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2008 | 385 | 0.070 |
Why?
|
| Bile Duct Diseases | 1 | 2006 | 17 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 1248 | 0.070 |
Why?
|
| Heterozygote | 3 | 2008 | 682 | 0.070 |
Why?
|
| Oxygen | 1 | 2010 | 550 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 4308 | 0.070 |
Why?
|
| Dyspnea | 1 | 2007 | 149 | 0.070 |
Why?
|
| Thioguanine | 2 | 2004 | 21 | 0.070 |
Why?
|
| Research Design | 1 | 2010 | 654 | 0.070 |
Why?
|
| Zinc | 1 | 2007 | 128 | 0.070 |
Why?
|
| Antigens | 1 | 2006 | 156 | 0.070 |
Why?
|
| Indomethacin | 1 | 2006 | 84 | 0.070 |
Why?
|
| Ovalbumin | 1 | 2006 | 318 | 0.070 |
Why?
|
| DNA | 2 | 2005 | 1608 | 0.070 |
Why?
|
| Pregnancy | 4 | 2022 | 7126 | 0.070 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2006 | 11 | 0.070 |
Why?
|
| Infusions, Intravenous | 3 | 2014 | 539 | 0.070 |
Why?
|
| Sick Role | 1 | 2005 | 31 | 0.060 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2005 | 31 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2006 | 170 | 0.060 |
Why?
|
| Esophagoscopy | 1 | 2006 | 158 | 0.060 |
Why?
|
| Depressive Disorder | 2 | 2005 | 450 | 0.060 |
Why?
|
| Esterification | 1 | 2005 | 13 | 0.060 |
Why?
|
| Adoptive Transfer | 1 | 2006 | 237 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 232 | 0.060 |
Why?
|
| Mycophenolic Acid | 1 | 2005 | 51 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2005 | 173 | 0.060 |
Why?
|
| Reoperation | 1 | 2008 | 813 | 0.060 |
Why?
|
| Child Abuse | 1 | 2007 | 192 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2008 | 1617 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 181 | 0.060 |
Why?
|
| Intellectual Disability | 1 | 2012 | 1043 | 0.060 |
Why?
|
| Retinoid X Receptors | 1 | 2004 | 33 | 0.060 |
Why?
|
| Family | 1 | 2008 | 572 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2006 | 271 | 0.060 |
Why?
|
| Salivary Glands, Minor | 1 | 2004 | 11 | 0.060 |
Why?
|
| Viremia | 2 | 2009 | 128 | 0.060 |
Why?
|
| Lip | 1 | 2004 | 15 | 0.060 |
Why?
|
| Feedback, Physiological | 1 | 2004 | 69 | 0.060 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2004 | 101 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2009 | 510 | 0.060 |
Why?
|
| Intestine, Small | 2 | 2001 | 313 | 0.060 |
Why?
|
| Gene Frequency | 1 | 2006 | 708 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2006 | 385 | 0.060 |
Why?
|
| Tretinoin | 1 | 2004 | 117 | 0.060 |
Why?
|
| Adolescent Health Services | 1 | 2004 | 38 | 0.060 |
Why?
|
| Algorithms | 2 | 2010 | 1583 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2006 | 672 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2006 | 351 | 0.060 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2004 | 84 | 0.060 |
Why?
|
| Cholanes | 1 | 2003 | 1 | 0.060 |
Why?
|
| Perioperative Care | 1 | 2006 | 196 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 401 | 0.060 |
Why?
|
| Cholestanols | 1 | 2003 | 2 | 0.060 |
Why?
|
| Genes, Dominant | 1 | 2004 | 245 | 0.060 |
Why?
|
| Puberty | 1 | 2004 | 94 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 1 | 2003 | 50 | 0.060 |
Why?
|
| Sirolimus | 1 | 2005 | 220 | 0.050 |
Why?
|
| Epoxide Hydrolases | 1 | 2003 | 33 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2018 | 757 | 0.050 |
Why?
|
| Xanthomatosis | 1 | 2003 | 7 | 0.050 |
Why?
|
| Acyltransferases | 1 | 2003 | 46 | 0.050 |
Why?
|
| Hypercholesterolemia | 2 | 2003 | 226 | 0.050 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2003 | 17 | 0.050 |
Why?
|
| Leupeptins | 1 | 2002 | 26 | 0.050 |
Why?
|
| Epilepsy | 1 | 2010 | 859 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 254 | 0.050 |
Why?
|
| Oocytes | 2 | 1995 | 291 | 0.050 |
Why?
|
| Malabsorption Syndromes | 1 | 2003 | 38 | 0.050 |
Why?
|
| Endoglin | 1 | 2022 | 22 | 0.050 |
Why?
|
| Rats, Inbred Lew | 1 | 2002 | 71 | 0.050 |
Why?
|
| Self Administration | 3 | 2008 | 42 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 611 | 0.050 |
Why?
|
| Androstadienes | 1 | 2002 | 49 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2023 | 235 | 0.050 |
Why?
|
| Afibrinogenemia | 1 | 2002 | 11 | 0.050 |
Why?
|
| Crigler-Najjar Syndrome | 1 | 2002 | 2 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 2048 | 0.050 |
Why?
|
| Choledochal Cyst | 1 | 2002 | 8 | 0.050 |
Why?
|
| Live Birth | 1 | 2022 | 54 | 0.050 |
Why?
|
| Short Bowel Syndrome | 1 | 2002 | 60 | 0.050 |
Why?
|
| Contraindications | 1 | 2002 | 77 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2002 | 152 | 0.050 |
Why?
|
| Prednisone | 1 | 2002 | 273 | 0.050 |
Why?
|
| Health Education | 1 | 2023 | 222 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2022 | 209 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2005 | 483 | 0.050 |
Why?
|
| Glucuronosyltransferase | 1 | 2002 | 70 | 0.050 |
Why?
|
| Biological Transport, Active | 3 | 2000 | 87 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 1 | 2002 | 213 | 0.050 |
Why?
|
| Steroids | 1 | 2002 | 203 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2006 | 706 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2008 | 854 | 0.050 |
Why?
|
| Weaning | 1 | 2001 | 40 | 0.050 |
Why?
|
| Cholecystectomy | 1 | 2001 | 56 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 1021 | 0.050 |
Why?
|
| Hyperammonemia | 1 | 2021 | 60 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 999 | 0.050 |
Why?
|
| Monitoring, Physiologic | 2 | 2018 | 360 | 0.050 |
Why?
|
| Safety | 1 | 2001 | 217 | 0.050 |
Why?
|
| Codon, Nonsense | 1 | 2021 | 131 | 0.050 |
Why?
|
| Fatigue | 1 | 2022 | 218 | 0.050 |
Why?
|
| Gene Library | 1 | 2001 | 220 | 0.040 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2002 | 170 | 0.040 |
Why?
|
| Fatty Acids | 2 | 2003 | 339 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2005 | 555 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2010 | 907 | 0.040 |
Why?
|
| Models, Animal | 1 | 2002 | 467 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2002 | 222 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2002 | 169 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2022 | 185 | 0.040 |
Why?
|
| Societies, Pharmaceutical | 1 | 2019 | 11 | 0.040 |
Why?
|
| Dogs | 2 | 1998 | 770 | 0.040 |
Why?
|
| Drug Industry | 1 | 2019 | 45 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 300 | 0.040 |
Why?
|
| Aged | 3 | 2014 | 18998 | 0.040 |
Why?
|
| Lipids | 1 | 2003 | 512 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 1073 | 0.040 |
Why?
|
| Fourier Analysis | 1 | 1999 | 61 | 0.040 |
Why?
|
| Ribavirin | 1 | 1999 | 79 | 0.040 |
Why?
|
| Psychometrics | 2 | 2017 | 666 | 0.040 |
Why?
|
| Diarrhea | 1 | 2001 | 320 | 0.040 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 1998 | 19 | 0.040 |
Why?
|
| Genome, Human | 1 | 2006 | 1261 | 0.040 |
Why?
|
| Colesevelam Hydrochloride | 1 | 1998 | 4 | 0.040 |
Why?
|
| Physicians | 1 | 2005 | 583 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 2000 | 450 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 1999 | 147 | 0.040 |
Why?
|
| Exons | 1 | 2001 | 795 | 0.040 |
Why?
|
| Cephalometry | 1 | 2018 | 33 | 0.040 |
Why?
|
| Digestive System | 1 | 1998 | 60 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 999 | 0.040 |
Why?
|
| Incidence | 3 | 2015 | 3040 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2006 | 997 | 0.040 |
Why?
|
| DNA Primers | 2 | 2001 | 669 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2018 | 172 | 0.040 |
Why?
|
| Nuclear Proteins | 2 | 2003 | 1283 | 0.040 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1997 | 68 | 0.040 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 1997 | 21 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 78 | 0.040 |
Why?
|
| Motor Skills | 1 | 2018 | 84 | 0.040 |
Why?
|
| Bile Duct Neoplasms | 2 | 2010 | 112 | 0.040 |
Why?
|
| Cholangiocarcinoma | 2 | 2010 | 110 | 0.040 |
Why?
|
| Drainage | 2 | 2014 | 254 | 0.040 |
Why?
|
| Gestational Age | 1 | 2021 | 1119 | 0.040 |
Why?
|
| Global Health | 2 | 2016 | 557 | 0.040 |
Why?
|
| Corticosterone | 1 | 1997 | 61 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 1997 | 55 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 1997 | 382 | 0.040 |
Why?
|
| Depression | 1 | 2005 | 1220 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2016 | 85 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 85 | 0.030 |
Why?
|
| Kinetics | 2 | 2015 | 1316 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1999 | 576 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 141 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2016 | 255 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1997 | 623 | 0.030 |
Why?
|
| Rickets | 1 | 2015 | 9 | 0.030 |
Why?
|
| Child Health Services | 1 | 2016 | 86 | 0.030 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1996 | 80 | 0.030 |
Why?
|
| Radioisotope Dilution Technique | 1 | 2015 | 43 | 0.030 |
Why?
|
| Reticulocytes | 1 | 1995 | 42 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2015 | 56 | 0.030 |
Why?
|
| Deuterium | 1 | 2015 | 103 | 0.030 |
Why?
|
| Xenopus laevis | 1 | 1995 | 122 | 0.030 |
Why?
|
| Enterostomy | 1 | 2014 | 5 | 0.030 |
Why?
|
| New York | 1 | 2014 | 66 | 0.030 |
Why?
|
| Body Weight | 1 | 2018 | 966 | 0.030 |
Why?
|
| Jejunum | 1 | 2015 | 128 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 1995 | 212 | 0.030 |
Why?
|
| Organ Specificity | 1 | 1995 | 428 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1034 | 0.030 |
Why?
|
| Internet | 1 | 2016 | 376 | 0.030 |
Why?
|
| Swine | 1 | 2016 | 1158 | 0.030 |
Why?
|
| Mannitol | 1 | 1993 | 48 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 2013 | 49 | 0.030 |
Why?
|
| Steroid 12-alpha-Hydroxylase | 2 | 2003 | 6 | 0.030 |
Why?
|
| Cognition | 1 | 2018 | 734 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2006 | 771 | 0.030 |
Why?
|
| Ligands | 2 | 2005 | 535 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 554 | 0.030 |
Why?
|
| Hepatic Encephalopathy | 1 | 2013 | 75 | 0.030 |
Why?
|
| Hospitals | 1 | 2015 | 397 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 670 | 0.020 |
Why?
|
| Introns | 2 | 2003 | 302 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1995 | 668 | 0.020 |
Why?
|
| Survivors | 1 | 2014 | 346 | 0.020 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2012 | 69 | 0.020 |
Why?
|
| Diet | 1 | 1998 | 1112 | 0.020 |
Why?
|
| Acetaminophen | 1 | 2012 | 92 | 0.020 |
Why?
|
| Hemolysis | 1 | 1991 | 105 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2011 | 114 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2011 | 107 | 0.020 |
Why?
|
| Comorbidity | 2 | 2007 | 1491 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 697 | 0.020 |
Why?
|
| Alleles | 2 | 2008 | 1599 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2002 | 135 | 0.020 |
Why?
|
| Streptozocin | 1 | 2010 | 25 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2011 | 180 | 0.020 |
Why?
|
| Hemoglobins | 1 | 1991 | 301 | 0.020 |
Why?
|
| Meconium Aspiration Syndrome | 1 | 1989 | 11 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 660 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2006 | 2443 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1991 | 1006 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 516 | 0.020 |
Why?
|
| Cyclosporins | 1 | 1989 | 74 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 238 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2015 | 995 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 504 | 0.020 |
Why?
|
| Enoxaparin | 1 | 2008 | 42 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 581 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 1989 | 169 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 133 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2008 | 70 | 0.020 |
Why?
|
| Plasma Exchange | 1 | 2008 | 83 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2009 | 492 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 277 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2006 | 34 | 0.020 |
Why?
|
| Kidney Tubules, Distal | 1 | 2006 | 17 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 2006 | 20 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2006 | 63 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 2007 | 186 | 0.020 |
Why?
|
| New York City | 1 | 2005 | 58 | 0.020 |
Why?
|
| United Kingdom | 1 | 2006 | 194 | 0.020 |
Why?
|
| Epithelium | 1 | 2006 | 373 | 0.020 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2006 | 112 | 0.020 |
Why?
|
| Calcium Channels | 1 | 2006 | 160 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2010 | 316 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2005 | 105 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2005 | 90 | 0.020 |
Why?
|
| Insulin | 1 | 2010 | 1196 | 0.020 |
Why?
|
| Deoxycholic Acid | 1 | 2005 | 13 | 0.020 |
Why?
|
| Digestive System Abnormalities | 1 | 2005 | 32 | 0.020 |
Why?
|
| Specialization | 1 | 2005 | 76 | 0.020 |
Why?
|
| Calcineurin Inhibitors | 1 | 2005 | 28 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2005 | 65 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2006 | 210 | 0.020 |
Why?
|
| Attitude | 1 | 2005 | 119 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2006 | 173 | 0.020 |
Why?
|
| Length of Stay | 2 | 2001 | 1281 | 0.010 |
Why?
|
| Hemosiderin | 1 | 2004 | 2 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1680 | 0.010 |
Why?
|
| Frozen Sections | 1 | 2004 | 24 | 0.010 |
Why?
|
| Medicine | 1 | 2005 | 97 | 0.010 |
Why?
|
| Aspirin | 1 | 2006 | 224 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2006 | 437 | 0.010 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2004 | 32 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 512 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2004 | 55 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 471 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1717 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 2005 | 139 | 0.010 |
Why?
|
| Anticholesteremic Agents | 1 | 2006 | 230 | 0.010 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2005 | 202 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 1380 | 0.010 |
Why?
|
| Growth | 1 | 2004 | 107 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2008 | 585 | 0.010 |
Why?
|
| Surface Tension | 1 | 2003 | 5 | 0.010 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2003 | 23 | 0.010 |
Why?
|
| Liver X Receptors | 1 | 2003 | 20 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2003 | 28 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 474 | 0.010 |
Why?
|
| Biotransformation | 1 | 2003 | 49 | 0.010 |
Why?
|
| Zonula Occludens-2 Protein | 1 | 2003 | 8 | 0.010 |
Why?
|
| Carps | 1 | 2003 | 10 | 0.010 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2003 | 37 | 0.010 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2003 | 42 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 6343 | 0.010 |
Why?
|
| Sterols | 1 | 2003 | 16 | 0.010 |
Why?
|
| Genomic Imprinting | 1 | 2004 | 123 | 0.010 |
Why?
|
| Tight Junctions | 1 | 2003 | 37 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 404 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2006 | 330 | 0.010 |
Why?
|
| Body Height | 1 | 2004 | 205 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 2005 | 229 | 0.010 |
Why?
|
| Isoelectric Focusing | 1 | 2002 | 24 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 439 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 317 | 0.010 |
Why?
|
| Receptors, LDL | 1 | 2003 | 90 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2003 | 285 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2003 | 306 | 0.010 |
Why?
|
| Perfusion | 1 | 2003 | 197 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2005 | 423 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 339 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2003 | 269 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2002 | 204 | 0.010 |
Why?
|
| RNA Splice Sites | 1 | 2002 | 87 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 2001 | 93 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 1760 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2002 | 388 | 0.010 |
Why?
|
| Family Health | 1 | 2002 | 258 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2001 | 19 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 2001 | 65 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2003 | 372 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2001 | 99 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2003 | 354 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 2005 | 779 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2001 | 121 | 0.010 |
Why?
|
| Cholic Acid | 1 | 2000 | 17 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 1440 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 751 | 0.010 |
Why?
|
| Rats, Inbred Strains | 2 | 1991 | 229 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 658 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2002 | 528 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 2000 | 86 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 2321 | 0.010 |
Why?
|
| Caregivers | 1 | 2004 | 563 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 3299 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1998 | 136 | 0.010 |
Why?
|
| Necrosis | 1 | 1998 | 212 | 0.010 |
Why?
|
| Cell Polarity | 1 | 1998 | 125 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2000 | 238 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1998 | 444 | 0.010 |
Why?
|
| Genomics | 1 | 2005 | 1472 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 1998 | 348 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1998 | 773 | 0.010 |
Why?
|
| Proteolipids | 1 | 1991 | 7 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1991 | 153 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1991 | 312 | 0.010 |
Why?
|
| Cell Separation | 1 | 1991 | 240 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1989 | 339 | 0.000 |
Why?
|